Kategorie: Zhoubné nádory prsu
Téma: 01. Predikce účinnosti léčiv směřovaných do EGFR/HER rodiny
Číslo abstraktu: 006
Autoři: Prof. MUDr. Pavol Žúbor, DrSc.; Prof. MUDr. Ján Danko, CSc.; A. Vojvodová; doc. MUDr. Karol Kajo, Ph.D.; N. Szunyogh; Ing. Zuzana Kviatkovská; S. Galo; MUDr. Katarína Macháleková, Ph.D.; K. Biringer; RNDr. Martina Barthová, Ph.D.; C.A. Dussan; Prof. MUDr. Lukáš Plank, CSc.
The aim of this case-control based prospective study was to determine the distribution of HER-2 genotype and its association with risk factors of breast cancer in the population of Slovak women. HER-2 genotypes were determined with PCR – RFLP method. The DNA was isolated from white blood cell nuclei.
The frequency of Val allele in the cancer group was 29.51 % and was higher than in the control group 15.49 % (p < 0.05). The presence of the heterozygote (Ile/Val) genotype was identified in 45.90 % of patients in the case group and in 28.17 % in healthy individuals, and the homozygote (Val/Val) genotype in 6.56 % and 1.41 %, respectively (p < 0.001). The risk of breast cancer development for carriers of one valine (Val) allele in genotype was nearly three-times lower (OR = 2.41) than for carriers of two Val alleles (OR = 6.89) (p < 0.01). Risk of cancer genesis for Val allele carriers was higher in multiparas (OR = 2.78), among women with positive family history of breast cancer (OR = 5.4), BMI > 24 (kg/m2) (OR = 5.8), late menopause (OR = 1.6), and early onset of menarche (OR = 1.2).
This study revealed relatively high frequency of the Val allele among the Slovak women population. Ile655Val polymorphism of HER-2 gene was associated with a statistically significantly increased risk of breast cancer all above in homozygotes for Val allele.
Acknowledgements: We would like to express our gratitude to the patients participated in this study. This work was supported by grant of Comenius University no. 22/2004.
Datum přednesení příspěvku: 9. 12. 2005